De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed
Language English Country Germany Media print-electronic
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- MeSH
- Diabetes Mellitus, Type 2 epidemiology genetics MeSH
- Genetic Predisposition to Disease MeSH
- Genetic Testing MeSH
- Hepatocyte Nuclear Factor 1-alpha genetics MeSH
- Hepatocyte Nuclear Factor 4 genetics MeSH
- Germinal Center Kinases MeSH
- Humans MeSH
- Mutation * MeSH
- Prevalence MeSH
- Protein Serine-Threonine Kinases genetics MeSH
- Pedigree MeSH
- Sequence Analysis, DNA MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Slovakia epidemiology MeSH
- Names of Substances
- Hepatocyte Nuclear Factor 1-alpha MeSH
- Hepatocyte Nuclear Factor 4 MeSH
- HNF1A protein, human MeSH Browser
- HNF4A protein, human MeSH Browser
- Germinal Center Kinases MeSH
- Protein Serine-Threonine Kinases MeSH
AIMS/HYPOTHESIS: MODY is mainly characterised by an early onset of diabetes and a positive family history of diabetes with an autosomal dominant mode of inheritance. However, de novo mutations have been reported anecdotally. The aim of this study was to systematically revisit a large collection of MODY patients to determine the minimum prevalence of de novo mutations in the most prevalent MODY genes (i.e. GCK, HNF1A, HNF4A). METHODS: Analysis of 922 patients from two national MODY centres (Slovakia and the Czech Republic) identified 150 probands (16%) who came from pedigrees that did not fulfil the criterion of two generations with diabetes but did fulfil the remaining criteria. The GCK, HNF1A and HNF4A genes were analysed by direct sequencing. RESULTS: Mutations in GCK, HNF1A or HNF4A genes were detected in 58 of 150 individuals. Parents of 28 probands were unavailable for further analysis, and in 19 probands the mutation was inherited from an asymptomatic parent. In 11 probands the mutations arose de novo. CONCLUSIONS/INTERPRETATION: In our cohort of MODY patients from two national centres the de novo mutations in GCK, HNF1A and HNF4A were present in 7.3% of the 150 families without a history of diabetes and 1.2% of all of the referrals for MODY testing. This is the largest collection of de novo MODY mutations to date, and our findings indicate a much higher frequency of de novo mutations than previously assumed. Therefore, genetic testing of MODY could be considered for carefully selected individuals without a family history of diabetes.
See more in PubMed
Diabetes Res Clin Pract. 2011 Jul;93(1):e41-3 PubMed
Eur J Endocrinol. 2010 May;162(5):987-92 PubMed
Nature. 1996 Dec 5;384(6608):458-60 PubMed
Diabetes Care. 2012 Jun;35(6):1206-12 PubMed
Diabetologia. 2007 Feb;50(2):325-33 PubMed
Diabetes. 1997 Jun;46(6):1081-6 PubMed
Diabetologia. 2008 Apr;51(4):546-53 PubMed
Diabetologia. 2005 May;48(5):878-85 PubMed
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7698-702 PubMed
Pediatr Diabetes. 2009 Sep;10 Suppl 12:33-42 PubMed
Clinical implications of the glucokinase impaired function - GCK MODY today
How can maturity-onset diabetes of the young be identified among more common diabetes subtypes?
Hidden MODY-Looking for a Needle in a Haystack
